GlassScriptPhysician profile
Adam Whitnel Bostick
NPI 1740496041
$2,796.95
in general payments reported to CMS, 2019-2025
34 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $131 · 2022: $391 · 2023: $602 · 2024: $328 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.41 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $585.55 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $232.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.11 | 2019-2025 | Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.81 | 2019-2022 | |
| Insmed, INC. | $176.68 | 2022-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $159.51 | 2022-2025 | Dupixent, Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $136.00 | 2022-2025 | Glassia, Cuvitru, Hyqvia |
| Abbott Laboratories | $107.93 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $91.58 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $88.50 | 2022-2023 | Opsumit |
| Sunovion Pharmaceuticals INC. | $74.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.32 | 2019-2025 | Zerbaxa, Dificid |
| Abbvie INC. | $61.89 | 2022-2023 | Teflaro, Avycaz |
| Grifols USA, LLC | $61.68 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Genentech USA, INC. | $52.95 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vital Connect, INC | $52.25 | 2022 | |
| Electromed, INC. | $48.98 | 2024 | Smartvest |
| Pfizer INC. | $48.67 | 2023 | |
| Philips North America LLC | $47.41 | 2019 | |
| Verona Pharma, INC. | $38.58 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $35.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.09 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $28.90 | 2022 | |
| United Therapeutics Corporation | $24.90 | 2023 | Tyvaso |
| Fisher & Paykel Healthcare INC | $24.55 | 2023 | Fisher & Paykel Healthcare |
| Allergan, INC. | $22.25 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.93 | 2019 | |
| Viatris Specialty LLC | $17.28 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $15.86 | 2020 | |
| Paratek Pharmaceuticals, INC. | $15.10 | 2024 | Nuzyra |
| Nabriva Therapeutics, Plc | $14.33 | 2020 | |
| Circassia INC. | $13.56 | 2019 | |
| Biomerieux INC | $8.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bostick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.